News & Events about Finch Therapeutics Group Inc.
BOSTON, June 09, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch, Finch Therapeutics or the Company) (Nasdaq: FNCH), a microbiome technology company with a portfolio of intellectual property and microbiome assets, today announced it will effect a one-for-30 reverse stock split of its ...
Atara Biotherapeutics (NASDAQ:ATRA Get Rating) and Finch Therapeutics Group (NASDAQ:FNCH Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, ...
Globe Newswire
4 months ago
SOMERVILLE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (the Company, Finch, or Finch Therapeutics) (Nasdaq: FNCH) today announced its decision to discontinue the PRISM4 Phase 3 trial of CP101 in recurrent C. difficile infection (CDI) and focus on realizing the value of ...
Globe Newswire
7 months ago
SOMERVILLE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (Finch or Finch Therapeutics) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs, today ...
Finch Therapeutics Group, Inc. (NASDAQ:FNCH Get Rating) traded down 3% on Friday . The company traded as low as $1.58 and last traded at $1.59. 11,318 shares changed hands during mid-day trading, a decline of 97% from the average session volume of 344,381 shares. The stock had previously closed at $...